Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

sample size for clinical endpoint BE study of Brinzolamide 1% ophthalmic [Design Issues]

posted by kishpokuri – India, 2015-11-24 15:18 (3870 d 00:18 ago) – Posting: # 15665
Views: 8,180

Hi all,
Can anyone suggest the appropriate sample size for a clinical endpoint bioequivalence study of Brinzolamide 1% ophthalmic suspension in chronic open angle glaucoma patients.
OGD guidelines has not mentioned regarding this. :confused:

Thank you,
Regards,
Dr. Kishan PV

Edit: Category changed. [Helmut]

Complete thread:

sample size for clinical endpoint BE study of Brinzolamide 1% ophthalmickishpokuri 2015-11-24 14:18
- general remark ElMaestro 2015-11-24 16:50
- Specific remarks d_labes 2015-11-25 11:23
  - Specific remarks kishpokuri 2015-11-27 13:46

Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
261 visitors (0 registered, 261 guests [including 24 identified bots]).
Forum time: 16:36 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas. Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz

Bioequivalence and Bioavailability Forum

sample size for clini­cal endpoint BE study of Brinzol­amide 1% ophthal­mic [Design Issues]

Complete thread:

sample size for clinical endpoint BE study of Brinzolamide 1% ophthalmic [Design Issues]